Register Now: Beyond EDC: Designing a Connected Data Strategy for Predictive Clinical Development
Commentary|Videos|August 24, 2026

Why Payment Performance Has Become a Competitive Differentiator for Sponsors

In this video interview, Patrick Mizer, chief technology officer at Ledger Run, explains how the shift from competing for patients to competing for high-performing sites has made payment reliability an operational brand—and a real factor in which sponsors get prioritized.

In a recent video interview with Applied Clinical Trials, Patrick Mizer, chief technology officer at Ledger Run, discussed how payment reliability has quietly become one of the most consequential competitive differentiators in clinical research—and why the infrastructure behind site payments is overdue for a fundamental redesign. He opened by reframing the competitive dynamic in clinical research: as experienced sites gain more study opportunities than they can support, sponsors are increasingly competing not just for patients but for the attention of high-performing investigative sites. In that environment, payment performance has become an operational brand—and sponsors with a reputation for predictable, accurate payments are gaining an advantage in site selection.

Mizer traced the persistence of payment inconsistency to decades of incremental growth without intentional design. Study budgets, contracts, CTMS platforms, EDC systems, and financial systems have remained disconnected, each introducing its own manual processes and assumptions. The operational pain, he noted, has historically been distributed widely enough across sponsors, CROs, and sites that no single party felt compelled to fix it wholesale.

On AI, Mizer was measured but specific. Skeptical of broad claims about AI's transformative potential—he invoked the pets.com era as an analogy—he described where AI is genuinely effective today as low-level reasoning tasks that are labor intensive, have QC built in, and don't yet require true expert judgment. Invoice processing is Ledger Run's proof point: 60% of customer time was being spent reading, translating, and manually entering invoices. The company built an agentic AI flow that ingests emailed invoices, screens for PHI, decomposes the components, and validates them against the system—with accuracy high enough that QC experts could not distinguish AI outputs from human work in blind testing.

He closed by connecting payment infrastructure directly to the broader site access problem, noting that with 80% of sites operating on six months or less of cash, the urgency is clear—and that the industry's growing investment in workflow modernization and agentic AI is a sign that the problem is finally being treated with the priority it deserves.


Related to this article

© photon_photo - © photon_photo - stock.adobe.com
Standardized measurement across five oncology centers found that clinical research coordinators rated eSource-enabled workflows positively (Overall Mean Satisfaction 5.79 of 7), with reduced manual entry and electronic data transfer earning strong marks, while perceived reduction in sponsor and monitor queries lagged as the one domain below threshold.
What Expanding AI Ecosystems Mean for Sponsor Complexity and Oversight
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, argues that CROs must act as orchestrators rather than aggregators—and that the real test of any AI ecosystem is whether it reduces sponsor coordination burden or just hands it back to them.
Where the Industry Is Headed as Clinical, Operational, and Real-World Data Connect
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, describes the industry’s trajectory toward a unified intelligence orchestration environment—and explains why the future isn’t one model that knows everything, but a trusted system that brings the right evidence to the right human decision.
Where AI Governance in Clinical Development Falls Short
In this video interview, Rajneesh Patil, global head of AI, digital, and innovation in clinical development at Syneos Health, identifies three recurring failure modes in AI governance frameworks—and explains why responsible AI must be an ongoing operating discipline, not a one-time approval gate.